YOUR SEARCH FOR Text 27 RESULTS
1 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… of $728 million in Q1’22 (+20% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $544 … to $2.40 billion Robust uptake of Opzelura™ (ruxolitinib) cream with over 38,000 new patients …
2 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… and $2.891 billion (+17%) in FY’21 Jakafi ® (ruxolitinib) net product revenues of $592 … for 2022 Successful U.S. launch of Opzelura™ (ruxolitinib) cream in atopic dermatitis with …
3 of Total
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance
… revenues of $3.4 billion (+14% Y/Y) – Jakafi ® (ruxolitinib) net revenues of $647 million (+9% … $2.53 - $2.63 billion for FY 2023 – Opzelura™ (ruxolitinib) Cream net revenues of $61 million …
4 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… in Q2 2021 (+17% vs Q2 2020) - Jakafi ® (ruxolitinib) revenues of $529 million in Q2 2021 … Phase 3 TRuE-V1 and TRuE-V2 studies evaluating ruxolitinib cream in vitiligo met primary and …
5 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… million in Q1 2021 (+6% vs Q1 2020) Jakafi ® (ruxolitinib) revenues of $466 million in Q1 … Review, including potential approval of ruxolitinib cream in the U.S. for atopic …
6 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… revenues of $664 million (+15% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $598 … new range of $2.36 to $2.40 billion Opzelura ™ (ruxolitinib) cream approved as first and only …
7 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… the second quarter (Q2'23) (+25% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $682 … $2.58 - $2.63 billion for FY 2023 Opzelura ® (ruxolitinib) cream net product revenues of $80 …
8 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… of $693 million in Q1'23 (+14% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $580 … $2.55 - $2.63 billion for FY 2023 – Opzelura ® (ruxolitinib) cream approved as the first and …
9 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura ™ (ruxolitinib) cream net product revenues – Jakafi …
10 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… revenues of $3.2 billion (+15% Y/Y) Jakafi ® (ruxolitinib) net revenues of $2.6 billion (+8%) … $2,690 - $2,750 million for FY 2024 Opzelura ® (ruxolitinib) cream net revenues of $109 million …